Goldman initiated coverage on Baxter with a new price target
$BAX
Medical/Dental Instruments
Health Care
Goldman initiated coverage of Baxter with a rating of Neutral and set a new price target of $36.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/31/2025 | Buy → Hold | Argus | |
| 8/4/2025 | $25.00 | Buy → Hold | Stifel |
| 8/1/2025 | $25.00 | Buy → Neutral | Goldman |
| 2/26/2025 | $42.00 | Buy | Goldman |
| 2/24/2025 | Hold → Buy | Argus | |
| 2/20/2025 | $39.00 | Overweight | Barclays |
| 7/15/2024 | $39.00 → $30.00 | Equal-Weight → Underweight | Morgan Stanley |
| 5/30/2024 | $36.00 | Neutral | Goldman |
Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced that it has increased the maximum purchase price for its $1.45 billion aggregate principal amount outstanding of 1.915% Senior Unsecured Notes due 2027 (the "2027 Notes") that it can repurchase under its previously announced cash tender offer for the 2027 Notes (the "2027 Notes Tender Offer") from $300 million to $600 million, on the terms and subject to the conditions set forth in the related Offer to Purchase dated Nov. 19, 2025 (the "Offer to Purchase"). The terms of the previously announced cash tender offer by Baxter for its 2.600% Senior Unsecured Notes due 2026 (the "2026 Notes Tender Offer" and, togethe
Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the commencement of tender offers, subject to the terms and conditions described below, to purchase for cash the debt securities issued by Baxter listed in the table below (collectively, the "Securities" and each a "series"). Subject to market conditions, the tender offers are expected to be funded using a portion of the proceeds from a concurrent offering of senior unsecured notes by the Company (the "New Notes"). The Company intends to use the remaining proceeds from the concurrent public offering of the New Notes to repay other indebtedness, including any remaining 2026 Notes and its outstanding term loan cr
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.01 per share of common stock. The dividend is payable on Jan. 2, 2026, to stockholders of record as of Nov. 28, 2025. The indicated annual dividend rate equates to $0.04 per share of common stock. "As we previously announced in conjunction with third-quarter 2025 earnings, we will be reducing the quarterly dividend beginning in January 2026," said Joel Grade, Baxter's executive vice president and chief financial officer. "This action is expected to free up more than $300 million in annual cash flow, consistent with our prior commitments an
For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c
Argus downgraded Baxter from Buy to Hold
Stifel downgraded Baxter from Buy to Hold and set a new price target of $25.00
Goldman downgraded Baxter from Buy to Neutral and set a new price target of $25.00
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)
FWP - BAXTER INTERNATIONAL INC (0000010456) (Subject)
8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)
SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)
SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)
SC 13G - BAXTER INTERNATIONAL INC (0000010456) (Subject)
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250706840140/en/Andrew Hider Appointed Baxter's Next CEO Since 2017, Mr. Hider has served as
Amerant Bancorp Inc. (NYSE:AMTB) ("Amerant" or "the Company") and its subsidiary, Amerant Bank, N.A. (the "Bank"), today announced the appointment of two accomplished executives, Patricia "Patty" Morrison and Jack Kopnisky, to the Board of Directors of the Company and the Bank. Their addition reflects the Company's continued commitment to strategic growth and further strengthening of the Board of Directors and executive management. "We are delighted to welcome both Patty and Jack to our Board of Directors," said Jerry Plush, Chairman and CEO of Amerant and the Bank. "Patty's deep technology leadership and extensive board expertise, paired with Jack's enviable experience in leading high pe
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca
Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced that it has increased the maximum purchase price for its $1.45 billion aggregate principal amount outstanding of 1.915% Senior Unsecured Notes due 2027 (the "2027 Notes") that it can repurchase under its previously announced cash tender offer for the 2027 Notes (the "2027 Notes Tender Offer") from $300 million to $600 million, on the terms and subject to the conditions set forth in the related Offer to Purchase dated Nov. 19, 2025 (the "Offer to Purchase"). The terms of the previously announced cash tender offer by Baxter for its 2.600% Senior Unsecured Notes due 2026 (the "2026 Notes Tender Offer" and, togethe
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.01 per share of common stock. The dividend is payable on Jan. 2, 2026, to stockholders of record as of Nov. 28, 2025. The indicated annual dividend rate equates to $0.04 per share of common stock. "As we previously announced in conjunction with third-quarter 2025 earnings, we will be reducing the quarterly dividend beginning in January 2026," said Joel Grade, Baxter's executive vice president and chief financial officer. "This action is expected to free up more than $300 million in annual cash flow, consistent with our prior commitments an
Third-quarter sales from continuing operations of $2.84 billion increased 5% on a reported basis and 2% on an operational basis1,2 Third-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($0.10); adjusted diluted EPS from continuing operations of $0.69 Andrew Hider joined the company as president and chief executive officer (CEO), now leading the company's focus to drive continuous improvement and sustainable growth and create shareholder value Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2025. "I joined Baxter because it's a global healthcare leader – an iconic brand with an